We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Parameter Analysis Establish Prognosis for Brain Metastases Patients

By LabMedica International staff writers
Posted on 07 Oct 2015
Certain laboratory results, which have previously not been used specifically for this purpose, can help to predict survival in patients with newly diagnosed brain metastases and to decide on the most appropriate treatment strategy.

Brain metastases are secondary tumors that have spread from primary tumors at other sites in the body such as lungs, breast or skin, for example. More...
Approximately 40% of all patients with metastasized cancer develop metastases in their brain.

Scientists at the Medical University of Vienna (Austria ) conducted a study which included 1,201 patients with different primary cancers. They analyzed blood parameters that had not so far been included in oncological prognosis scores. The results show that subnormal levels of red blood pigment (hemoglobin), blood platelets (thrombocytes), white blood cells (leucocytes) and albumin (the main plasma protein) and elevated levels of serum creatinine, lactate dehydrogenase and the inflammatory markers C-reactive protein (CRP) were associated with poorer survival from brain metastases.

The commonest type of malignant brain tumors, are difficult to treat, often cause severe symptoms, such as intense headaches, neurological problems or epilepsy and are often associated with a limited life expectancy. Nevertheless, there are some patients who survive for a long time, despite their brain metastases. Anna Sophie Berghoff, PhD, the lead author of the study, said, “We asked ourselves whether there are any objective parameters that can provide us with a more stable basis for establishing an accurate prognosis for patients. This is not only important for estimating their life expectancy or for their inclusion in clinical studies but also for deciding on the most appropriate treatment for them.”

Dr. Berghoff, added, “This study has enabled us to show that the investigated parameters have a strong, independent prognostic impact and are therefore to be regarded as objective parameters. This is particularly true of hemoglobin levels and the concentration of CRP and lactate dehydrogenase." The team is now recommending that the last three parameters, in particular, be tested in follow-up studies for inclusion in prognosis scores. The study was presented at the European Cancer Congress ECC2015, held September 25–29, 2015, in Vienna (Austria).

Related Links:

Medical University of Vienna 



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.